Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared…
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared…
First half of 2023: sales of 118.0 million EUR (previous year: 106.8 million EUR) profit of 10.9 million EUR (previous…
According to preliminary, unaudited figures, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX)…
Based on initial, unaudited assessments, revenues of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Med…
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 mill…
Eckert & Ziegler Radiopharma GmbH (EZR), the radiopharmaceutical production arm of Eckert & Ziegler, has signed a joint…
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a record result in the first nine…
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a new record result in the first…
Based on initial, unaudited assessments, earnings of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Med…
One-off effects from the deconsolidation of the tumor irradiation business, a waning of the Corona slump, and continued…